Role of Unani drugs (Tiryaqe Wabai, Arque-e-Ajeeb, Habb-e- Loban) in the treatment of COVID-19 patients.

Adjuvant role of Unani formulations (Tiryaqe Wabai, Arque-e-Ajeeb, Habb-e- Loban) in the management of COVID-19 patients

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030825

Enrollment

Registered

2021-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Treatment with Tiryaqe Wabai, Arque-e Ajeeb and Habb-e- Loban : All the patients will receive treatment according to the standard treatment protocol of COVID-19 based on Ministry of He

Eligibility

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists (ASA) class I &II. Confirmed COVID-19 case (RT-PCR for SARS-CoV-2 positive).

Exclusion criteria

Exclusion criteria: Patient not consenting. Suspected COVID patient. American Society of Anesthesiologists (ASA) class III, IV & V. Pregnant and lactating women. History of Hypersensitivity/non-responsive to the study drug or any of its ingredients.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with 50% increase in mean ALC on day 15Timepoint: Day 15	—

Secondary

Measure	Time frame
Mortality rate.Timepoint: Day 30 and Day 45;Percentage of patients with 2 points improvement or becoming asymptomatic (Grade 2 or less) on the modified ordinal scale for clinical improvement for two groupsTimepoint: Day 15;Percentage of patients with adverse eventsTimepoint: NIL;Percentage of patients with Grade 1 on WHO modified ordinal scale confirmed (negative swab status).Timepoint: Day 7, Day 14 and Day 21;Proportion of patients with 50% increase in mean ALCTimepoint: Day 30 and Day45;Proportion of patients with 50% increase in mean CD4Timepoint: Day 15;Proportion of patients with 50% increase in mean CD8Timepoint: Day 15;Time to discharge from hospital/duration of hospitalization for inpatients for two groupsTimepoint: NIL;Time to resolution of all clinical symptoms of COVID-19 viral infection (Grade 2 on WHO modified ordinal scale) for two treatment armsTimepoint: NIL	—

Measure

Time frame

Mortality rate.Timepoint: Day 30 and Day 45;Percentage of patients with 2 points improvement or becoming asymptomatic (Grade 2 or less) on the modified ordinal scale for clinical improvement for two groupsTimepoint: Day 15;Percentage of patients with adverse eventsTimepoint: NIL;Percentage of patients with Grade 1 on WHO modified ordinal scale confirmed (negative swab status).Timepoint: Day 7, Day 14 and Day 21;Proportion of patients with 50% increase in mean ALCTimepoint: Day 30 and Day45;Proportion of patients with 50% increase in mean CD4Timepoint: Day 15;Proportion of patients with 50% increase in mean CD8Timepoint: Day 15;Time to discharge from hospital/duration of hospitalization for inpatients for two groupsTimepoint: NIL;Time to resolution of all clinical symptoms of COVID-19 viral infection (Grade 2 on WHO modified ordinal scale) for two treatment armsTimepoint: NIL

—

Countries

India

Contacts

Public ContactDr Ansul Kumar

Department of Cardiothoracic Surgery, RIMS

docansul@gmail.com9650965875

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026